Bezlotoxumab prevents extraintestinal organ damage induced by Clostridioides difficile infection
Clostridioides difficile is the most common cause of infectious antibiotic-associated diarrhea, with disease mediated by two major toxins TcdA and TcdB. In severe cases, systemic disease complications may arise, resulting in fatal disease. Systemic disease in animal models has been described, with t...
Main Authors: | Steven J. Mileto, Melanie L. Hutton, Sarah L. Walton, Antariksh Das, Lisa J. Ioannidis, Don Ketagoda, Kylie M. Quinn, Kate M. Denton, Diana S. Hansen, Dena Lyras |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-12-01
|
Series: | Gut Microbes |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2022.2117504 |
Similar Items
-
Outbreak of Clostridioides difficile infection in Silesian district hospital
by: Klaudia T. Szarek, et al.
Published: (2023-06-01) -
Efficacy of bezlotoxumab in preventing the recurrence of Clostridioides difficile infection: an Italian multicenter cohort study
by: Marianna Meschiari, et al.
Published: (2023-06-01) -
Bezlotoxumab in Patients with a Primary <i>Clostridioides difficile</i> Infection: A Literature Review
by: Guido Granata, et al.
Published: (2022-10-01) -
Real-World Experience with Bezlotoxumab for Prevention of Recurrence of <em>Clostridioides difficile</em> Infection
by: Rosa Escudero-Sánchez, et al.
Published: (2020-12-01) -
Genomic characterization of nine Clostridioides difficile strains isolated from Korean patients with Clostridioides difficile infection
by: Seung Woo Ahn, et al.
Published: (2021-09-01)